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Background: Cell-free DNAs (cfDNA) analysis may provide a non-invasive diagnostic 
approach for lung adenocarcinoma patients. CfDNA, short double-stranded DNA derived 
from noncancerous and cancer cells, circulates in the bloodstream and carries the genetic 
information of the cancer cells, including tumor-specific mutations. As liquid biopsy, non-
invasive approach for cancer diagnosis, cfDNA is one of the convenient blood-based 
biomaterials to be used. However, the low allele fraction (AF) of cfDNA derived from cancer 
cells is still challenging as it may affect the detection rate of mutation allele.  
Recently, droplet digital PCR (ddPCR) has been developed with high sensitivity for 
mutation analysis. This study evaluated the utility of ddPCR for cfDNA analysis to 
examine its detection rate as liquid biopsy and compared the results with tumor samples 
for the correlation with the malignant grade.  
 
Methods: Nineteen lung adenocarcinoma patients in Hiroshima University Hospital from 
2010-2017 were enrolled in this study. All patients underwent biopsy and were diagnosed as 
lung adenocarcinoma. EGFR gene status in the biopsy specimen was already evaluated by 
clamp PCR (13 L858R, 3 E746-A750del, and 3 negatives). Tumor DNA (tDNA) samples 
were isolated from 19 formalin-fixed paraffin-embedded (FFPE) primary or metastasis site 
samples. Among them, 14 samples were obtained by transbronchial lung biopsy (TBLB) 
procedure and 5 samples were obtained by surgical procedure. All biopsy samples were 
taken before chemotherapy. Immunohistochemistry using EGF receptor L858R mutant-
specific monoclonal rabbit antibody was conducted in 12 cases to evaluate the proportions of 
EGFR L858R-positive cells in each tumor. NCI-H1975 and Lc-Ad1 cell lines were used as 
positive and negative control, respectively. CfDNA was isolated from 17 serum samples 
taken at the time of diagnosis before starting chemotherapy. In addition, cfDNA was 
isolated from plasma samples of 4 healthy volunteers. CfDNA of healthy volunteers and 
placenta DNA were used for the detection limit of ddPCR assays analysis. CfDNA of 
healthy volunteers was used for the ddPCR false positive signal detection, while placenta 
DNA was used as negative control. NCI-H1975 and PC-9 cell lines were used as positive 
control for L858R and E746-A750del detection by ddPCR, respectively. Serial dilution of 
NCI-H1975 and PC9 cell lines with wild type human genomic DNA (placenta DNA) was 
performed to determine the detection limit of ddPCR assays. The detection limit was 
determined by the AF of the diluted cell line that was above that of cfDNA of healthy 
volunteers. 
 
Results: Detection limit of AFs by ddPCR was 0.024% for EGFR L858R and 0.003% for 
EGFR E746-A750del. In tDNA samples, EGFR point mutation and deletion were detected 
in 13/19 and 3/19 samples, respectively. In 17 cfDNA available cases, EGFR mutation and 
deletion were detected in 8/11 (61.5%) and 3/3 (100%) by ddPCR, respectively. In the 
remaining 3 negative cases, the tumor did not have EGFR L858R nor E746-A750del. 
Among cases where mutation was detectable in tDNA, AFs ranged from 5.7% to 71% (mean 
32.7%) for EGFR L858R and from 7.5% to 34.7% (mean 19.4%) for EGFR E746-A750del. 
AFs of EGFR L858R mutation in cfDNA samples ranged from 0.04% to 5.12% (mean 1.3%) 
and EGFR E746-A750del ranged from 0.07% to 18.6% (mean 6.3%). Compared to tDNA, 
AFs of cfDNA were low. 
The proportions of EGFR L858R-positive cells by immunohistochemistry in surgical 
samples ranged from 33.6% to 73.2% (mean 52.3%) and in TBLB samples ranged from 3.4% 
to 93% (mean 35.9%). AFs of tDNA by ddPCR and the proportions of EGFR L858R-positive 
cells by immunohistochemistry were relatively correlated (r = 0.53, p = 0.1, N = 12). 
However, no correlation was found between AFs of cfDNA and AFs of tDNA (r = -0.11, p = 
0.69, N = 17) and between AFs of cfDNA and the proportions of EGFR L858R-positive cells 
(r = -0.56, p = 0.09, N = 10). In primary tumor biopsy samples by TBLB procedure, the case 
with the lowest proportion of EGFR L858R-positive cells (16.1%) had the highest AF of 
cfDNA (5.12%). In contrast, the case with the highest proportion of EGFR L858R-positive 
cells (67.7%) had no detectable mutated AF in cfDNA. No significant correlation was shown 
between AF rates of mutations in cfDNA with any clinicopathological factors, including 
outcome, tumor size, lymph node metastasis, distant metastasis, and stage. However, when 
AFs of cfDNA were divided into two groups, ≤0.1% and >0.1%, all patients with AF of 
cfDNA >0.1% had lymph node metastasis and distant metastasis. 
 
Discussion: CfDNA derived from tumor cells is diluted with an abundant amount of cfDNA 
derived from normal cells, therefore, the AFs of mutation and deletion in cfDNA can be very 
low. Our study showed the ability of cfDNA analysis using ddPCR with high detection rate. 
The proportions of EGFR L858R-mutated cells in tissue samples relatively correlated with 
AFs of tDNA. However, no correlation was found between the AFs in cfDNA and tDNA. AFs 
of cfDNA may be associated with the characteristics of the tumor, such as lymph node 
metastasis and distant metastasis, instead of mutated cells number.  
In conclusion, cfDNA analysis by ddPCR enables high detection rates for EGFR L858R 
and E746-A750del. Therefore, patients with lung adenocarcinoma could be benefited by 
cfDNA analysis using ddPCR as it may provide complementary data to the tumor biopsy for 
precision medicine. 
 
